Full text is available at the source.
Abstract
Patients with type 2 diabetes mellitus undergoing dialysis have extremely high cardiovascular and mortality risks.
- Evidence for effective therapies in this population is limited.
- The impact of glucagon-like peptide-1 receptor agonists on health outcomes in these patients remains uncertain.
- There is a need for further investigation into potential treatments for this high-risk group.
Simplified